Skip to main content
SpringerLink
Log in

Bone Metastases: Epidemiology and Societal Effect

  • Chapter
Book cover Metastatic Bone Disease

Abstract

The incidence of skeletal metastases is increasing as survival from cancer increases. This introductory chapter looks at the epidemiology of metastatic bone disease and the impact of increasing survival of patients with cancer. The incidence of skeletal related events (SREs) and pathological fracture are reviewed from epidemiological data and the placebo wings of randomized trials of bisphosphonate therapy in metastatic bone disease. The economic and social burden of SREs in metastatic bone disease to health organizations, both patients and caregivers, and the wider economy are reviewed and updated to 2014 costs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Weber KL, Randall RL, Grossman S, Parvizi J. Management of lower-extremity bone metastasis. J Bone Joint Surg. 2006;88 suppl 4:11–9.

    Article  PubMed  Google Scholar 

  2. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524–30.

    Article  PubMed  Google Scholar 

  3. American Cancer Society. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042801.pdf

  4. Li S et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012;4:87–93.

    PubMed Central  PubMed  Google Scholar 

  5. Yu HH, Tsai YY, Hoffe SE. Overview of diagnosis and management of metastatic disease to bone. Cancer Control. 2012;19:284–91.

    Google Scholar 

  6. Jacofsky DJ, Haidukewych GJ. Management of pathologic fractures of the proximal femur: state of the art. J Orthop Trauma. 2004;18(7):459–69.

    Article  PubMed  Google Scholar 

  7. Galasko C. The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert A, editors. Bone metastases. Boston: GK Hall; 1981. p. 49–63.

    Google Scholar 

  8. Swanson DA, Orovan WL, Johnson DE, Giacco G. Osseous metastases secondary to renal cell carcinoma. Urology. 1981;18(6):556–61.

    Article  CAS  PubMed  Google Scholar 

  9. Heymann D. Bone Cancer: Progression and Therapeutic Approaches. Google E-Book 2009

    Google Scholar 

  10. Raskin K.A. Surgical management of Upper Extremity Bone Metastases: A Treatment Algorithm. Orthopaedic Knowledge Update 3: Musculoskeletal Tumors (Editor: Biermann J.S.) AAOS 2014 [ISBN 9780892039685]; 339

    Google Scholar 

  11. Jensen AØ, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer. 2011;11:29.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–7.

    Article  PubMed  Google Scholar 

  13. Cetin K, Christiansen CF, Jacobsen JB, Nørgaard M, Sørensen HT. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer. 2014;86(2):247–54.

    Article  PubMed  Google Scholar 

  14. Yong M, Jensen AØ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat. 2011;129(2):495–503.

    Article  PubMed  Google Scholar 

  15. Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P. Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol. 2013;2(1):22–9.

    Article  Google Scholar 

  16. Ratasvuori M. Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis. Surg Oncol. 2013;22(2):132–8.

    Article  PubMed  Google Scholar 

  17. Oster G, Lamerato L, Glass AG, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013;21(12):3279–86.

    Article  PubMed  Google Scholar 

  18. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004;10(18):6397S–403S.

    Article  CAS  PubMed  Google Scholar 

  19. Kakhki VRD, Anvari K, Sadeghi R, Mahmoudian A-S, Torabian-Kakhki M. Pattern and distribution of bone metastases in common malignant tumors. Nucl Med Rev Cent East Eur. 2013;16(2):66–9.

    Article  PubMed  Google Scholar 

  20. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care. 2010;19:755–60.

    Article  CAS  Google Scholar 

  21. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer. 2000;88(5):1082–90.

    Article  CAS  PubMed  Google Scholar 

  22. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82.

    Article  CAS  PubMed  Google Scholar 

  23. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 2004;100(12):2613–21.

    Article  CAS  PubMed  Google Scholar 

  24. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2):593–602.

    CAS  PubMed  Google Scholar 

  25. Rose PS, Buchowski JM. Metastatic disease in the thoracic and lumbar spine: evaluation and management. J Am Acad Orthop Surg. 2011;19(1):37–48.

    PubMed  Google Scholar 

  26. Bauer HC, Wedin R. Survival after surgery for spinal and extremity metastases: prognostication in 241 patients. Acta Orthop. 1995;66(2):143–6.

    Article  CAS  Google Scholar 

  27. Hansen BH, Keller J, Laitinen M, Berg P, Skjeldal S, Trovik C, et al. The Scandinavian Sarcoma Group skeletal metastasis register survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop. 2004;75(S311):11–5.

    Article  CAS  Google Scholar 

  28. Coleman RE, Rubens R. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.

    Article  CAS  PubMed  Google Scholar 

  30. Joshi AD, Carter JA, Botteman MF, Kaura S. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom. Clin Ther. 2011;33(3):291–304.

    Article  PubMed  Google Scholar 

  31. Forbes GS, McLeod RA, Hattery RR. Radiographic manifestations of bone metastases from renal carcinoma. Am J Roentgenol. 1977;129(1):61–6.

    Article  CAS  Google Scholar 

  32. Damron TA, Ward WG. Risk of pathologic fracture: assessment. Clin Orthop Relat Res. 2003;415S:S208–11.

    Article  Google Scholar 

  33. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860–7.

    Article  PubMed  Google Scholar 

  34. Jalava T, Sarna S, Pylkkanen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res. 2003;18:1254–60.

    Article  PubMed  Google Scholar 

  35. Weinfurt KP, Li Y, Castel LD, Timbie JW, Glendenning A, Schulman KA. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2002;13 suppl 5:180.

    Google Scholar 

  36. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004;42(2):164–75.

    Article  PubMed  Google Scholar 

  37. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol. 2004;46(6):731–40.

    Article  PubMed  Google Scholar 

  38. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005;6(2):161–71.

    Article  PubMed  Google Scholar 

  39. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005;92(10):1869–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006;24(30):4895–900.

    Article  CAS  PubMed  Google Scholar 

  41. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008;14(5):317–22.

    PubMed  Google Scholar 

  42. Groot MT, Boeken Kruger CGG, Pelger RCM, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol. 2003;43(3):226–32.

    Article  CAS  PubMed  Google Scholar 

  43. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168(3):1005–7.

    Article  PubMed  Google Scholar 

  44. Riggs BL, Melton Iii LJ. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995;17(5):S505–11.

    Article  Google Scholar 

  45. American Cancer Society Cancer Facts and Figures 2005. http://www.cancer.org/acs/groups/content/@nho/documents/document/caff2005f4pwsecuredpdf.pdf

  46. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the US. Cancer. 2007;109(11):2334–42.

    Article  PubMed  Google Scholar 

  47. Cameron D. Patient management issues in metastatic bone disease. Semin Oncol. 2004;31:79–82.

    Article  PubMed  Google Scholar 

  48. Hechmati G et al. Cost of skeletal-related events in European patients with solid tumors and bone metastases: data from a prospective multinational observational study. J Med Econ. 2013;16(5):691–700.

    Article  CAS  PubMed  Google Scholar 

  49. Dahlberg L, Lundkvist J, Lindman H. Health care costs for treatment of disseminated breast cancer. Eur J Cancer. 2009;45(11):1987–91.

    Article  CAS  PubMed  Google Scholar 

  50. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer. 2000;36(6):724–35.

    Article  CAS  PubMed  Google Scholar 

  51. Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6S):75s–80s.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(1):23–7.

    Article  CAS  PubMed  Google Scholar 

  53. Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm. 2010;16(9):693.

    PubMed  Google Scholar 

  54. Foster TS, Miller JD, Boye ME, Blieden MB, Gidwani R, Russell MW. The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev. 2011;37(6):405–15.

    PubMed  Google Scholar 

  55. Lidgren M, Wilking N, Jonsson B, Rehnberg C. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care. 2007;23(2):223–31.

    Article  PubMed  Google Scholar 

  56. Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ. 2004;170(12):1795–801.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Fenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on survivors’ quality of life? J Oncol Pract. 2014;10(5):332–9.

    Article  PubMed  Google Scholar 

  58. Tharmalingam S, Chow E, Harris K, Hird A, Sinclair E. Quality of life measurement in bone metastases: a literature review. J Pain Re. 2008;2008(1):49–58.

    Google Scholar 

  59. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2006–14.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leicester Orthopaedics, University Hospitals of Leicester, Leicester, UK

    Robert U. Ashford MD, FRCS (Tr & Orth)

  2. Department of Orthopaedics, Huntsman Cancer Institute, Huntsman Cancer Hospital and Primary Children’s Hospital, Sarcoma Services, Suite 4260, 2000 Circle of Hope Drive, Salt Lake City, UT, 84112, USA

    R. Lor Randall MD

Authors
  1. Robert U. Ashford MD, FRCS (Tr & Orth)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Lor Randall MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Lor Randall MD .

Editor information

Editors and Affiliations

  1. Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah, USA

    R. Lor Randall

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ashford, R.U., Randall, R.L. (2016). Bone Metastases: Epidemiology and Societal Effect. In: Randall, R. (eds) Metastatic Bone Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5662-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5662-9_1

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5661-2

  • Online ISBN: 978-1-4614-5662-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation